Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study

Clicks: 1
ID: 320331
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #176 of 176 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 176 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Lebrikizumab, a monoclonal antibody targeting interleukin-13, has demonstrated efficacy and safety in adults with moderate-to-severe atopic dermatitis (AD), but data in elderly patients remain limited. We conducted a retrospective multicentre study including 90 patients aged ≥60 years with moderate-to-severe AD treated with lebrikizumab across 23 Italian dermatology centres. Clinical outcomes were assessed at baseline and at weeks (W)16, W24 and W52. Mean EASI decreased from 23.24 ± 7.93 at baseline to 6.33 ± 6.54 at W16, 3.57 ± 3.74 at W24 and 2.70 ± 4.83 at W52 (p < 0.0001). EASI75 was achieved by 58.4%, 82.0% and 87.0% of patients at W16, W24 and W52, respectively. Clinical responses were similar across age groups and independent of prior biologic or JAK inhibitor exposure. Adverse events occurred in 7.8% of patients and were mainly mild. These findings support the effectiveness and safety of lebrikizumab in elderly patients with AD in real-world clinical practice.
Reference Key
openalex_W7167794178 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors M A Napolitano, Giuseppe Lauletta, Marianna Cimmino, Giampiero Girolomoni, Elena Pezzolo, Silvia Mariel Ferrucci, Alessandra Narcisi, Alessandro Borghi, Ester Del Duca, Marco Romanelli, Laura Bonzano, Niccolò Gori, Ketty Peris, Filomena Mandato, Enzo Errichetti, Maria Esposito, Claudio Marasca, Mariateresa Rossi, Nicola Zerbinati, Giovanna Galdo, Tiziana Peduto, Simone Ribero, Michela Ortoncelli, Nicole Macagno, Maria MARIANO, Maria Concetta Fargnoli, Ilaria di Sessa, Massimo Gola, Nicola Milanesi, F Caroppo, Genoveffa Scotto Di Luzio, Paolo Calzari, Martina Maurelli, Raul Armando Luyo Saboya, Natale Schettini, Luigi Gargiulo, Matteo Bianco, Annunziata Dattola, Flavia Manzo Margiotta, Sara Triolo, Zeno Fratton, Andrea Carugno, Francesca di Vico, Cataldo Patruno
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag285
URL
https://doi.org/10.1093/ced/llag285
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.